Author: Climb Bio, Inc.

Posted Date:

April 8, 2026

Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026

Climb Bio, Inc.

April 8, 2026
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy

Climb Bio, Inc.

April 7, 2026
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Climb Bio, Inc.

March 5, 2026
Climb Bio to Present at Upcoming Investor Conferences

Climb Bio, Inc.

February 8, 2026